not for human or veterinary application
Every 10 units equals exactly 1 mg
FDA-era pediatric treatment program (1997) Children with growth hormone deficiency received nightly subQ sermorelin at 0.2-0.3 mg/day
Human clinical-trial data (Phase 1/2 studies in wound healing, cardiac injury, and dry eye) exist only for a different, full-length recombinant thymosin beta-4 product, not for the short synthetic fragment marketed as TB-500, so no completed published human trial has evaluated TB-500 specifically for muscle, tendon, or joint recovery
Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease
The enhanced energy and mental clarity you gain today can elevate your performance, mood, and overall quality of life